| Literature DB >> 30792805 |
Juan C Astigueta1,2, Milagros A Abad-Licham2,3,4, Folker M Agreda5, Benjamin A Leiva1, Jorge L De la Cruz6.
Abstract
Spontaneous regression of a primary testicular germ-cell tumour (GCT), over time known as 'Burned out', 'Shrinking Seminoma', 'pT0', 'Burnout' or 'Spontaneous Regression', is an uncommon, generally metastatic phenomenon, which may present elevated tumour markers and a suspicious testicular ultrasound image. The histological study of the testicle demonstrated morphological changes of complete or partial tumour regression and found fibrous scarring and other characteristic changes of this phenomenon, which in some cases include vestiges of GCT. There are few publications on testicular GCT tumour regression and those that exist present limited data on the biology of the disease and its etiopathogenesis. This entity was recently recognised in the latest edition of the World Health Organization's (WHO) Classification of Tumours. We present our clinical, imaging, laboratory, cytohistological and management experience, as well as a historical review of the literature.Entities:
Keywords: burned out; germ-cell tumour; spontaneous regression; testicle
Year: 2018 PMID: 30792805 PMCID: PMC6351062 DOI: 10.3332/ecancer.2018.888
Source DB: PubMed Journal: Ecancermedicalscience ISSN: 1754-6605
Epidemiological and clinical data.
| Case | Age (years) | Pathological history | Disease time | Principal signs and symptoms | Testicular examination | Admission Diagnosis |
|---|---|---|---|---|---|---|
| 54 | No | 6 months | Abd. tumour, lumbar and abdominal pain, WL. | Negative | Lymphoma | |
| 58 | No | 2 months | Sc. and abd. tumour, lumbar pain, inc. vol. LEs, WL. | Negative | Lymphoma | |
| 23 | No | 1 month | Haemoptysis and left WL hemiplegia | Negative | EAD Pulmonary Mets. | |
| 36 | No | 7 months | Abd. tumour, lumbar pain, WL., incr. left LE vol. | Negative | Metastatic GCT | |
| 20 | No | 3 months | Abd. tumour, abd. pain | Negative | Metastatic GCT |
WL. Weight loss; Abd.: abdominal; SC: supraclavicular; LEs Incr. Vol.: enlargement of limbs; Mets: metastasis; EAD: aetiology to be determined.
Imaging and tumour marker data at the initial diagnosis.
| Testicular ultrasound | CT abdomen/pelvis | CT thorax/brain | Doppler ultrasound vessels | Tumour markers | |||
|---|---|---|---|---|---|---|---|
| AFP (UI) | HCG (UI) | LDH (UI) | |||||
| RT with 23 mm× 26 mm × 12 mm. hypoec. nodule. | 17 cm × 10 cm × 8 cm. RTP Tumour, encompasses aorta and collapses cava | No metastasis | No DVT | Normal | Normal | 2480 | |
| RT with 8 mm × 7 mm hypoec. nodule. | 15 cm × 13 cm × 9 cm. RTP Tumour, encompasses the large vessels | Supraclavicular and mediastinal adenopathies | Cava and iliac DVT. | Normal | Normal | 3637 | |
| LT with 9 mm × 8 mm hypoec. pseudonodule | 11 cm × 7 cm × 4 cm. RTP Tumour, encompasses aorta and iliac | Multiple pulmonary and frontoparietal Mets. | No DVT | Normal | 19209 | 561 | |
| LT with 30 mm. hypoec. node. | 16 cm × 9 cm × 9cm RTP Tumour, encompasses large vessels | No metastasis | Iliac and left | Normal | Normal | 2480 | |
| LT with 5 mm × 10 mm isoec nodule. | 16 cm × 15 cm × 9 cm. RTP tumour in the left iliac region, encompasses vessels | No metastasis | No DVT | 1745 | 3705 | 2948 | |
RT: right testicle; LT: left testicle; hypoec.: hypoechogenic; RTP: retroperitoneal; DVT: deep vein thrombosis; Mets.: metastasis.
Figure 1.Imaging studies: (A) Ultrasound showing heterogeneous nodule and microcalcifications in the testicular parenchyma. (B) Tomography with retroperitoneal mass that encompasses large vessels.
Data on the management, anatomopathological diagnosis and state of the disease.
| Initial surgical management | AP (1) | Second procedure | AP(2) | Adjuvant Therapy | Time of follow-up | Status disease | |
|---|---|---|---|---|---|---|---|
| RTP tumour biopsy | Seminoma | Radical Orchiectomy | Fibrous scar | Chemo (BEP x 4) | 53 months | NED | |
| Supraclavicular tumour biopsy | Seminoma | Radical Orchiectomy | Fibrous scar | Chemo (BEP x 4) | 40 months | NED | |
| Pulmonary nodule biopsy | Choriocarcinoma | Radical Orchiectomy | Fibrous scar | Chemo + WBRT | 7 months | DOD | |
| Radical Orchiectomy | Fibrous scar | RTP tumour biopsy | Seminoma | Chemo (BEP x 4) | 16 months | NED | |
| Radical Orchiectomy | Fibrous scar | RTP tumour biopsy | Mixed (EC/YST/T) | Chemo (BEP x 4) | 3 months | AWD |
EC: embryonal carcinoma; YST: yolk sac tumour; T: teratoma; WBRT: whole brain radiotherapy; BEP: bleomycin/etoposide/platinum; NED: no evidence of disease; DOD: dead of disease; AWD: alive with disease; AP: anatomical pathology.
Figure 2.Histomorphological characteristics of testicular tumour regression: scar (blue) and paracicatricial area (orange). The case numbers are on the ‘Y’ axis.
Figure 3.Microphotographs of the histomorphological characteristics of the testicular tumour regression: (A) Fibrous scar with increased vascularity. (B) Increase in vascularity and microcalcifications. (C) Tubular hyalinosis and presence of Leydig cells. (D) Microliths in paracicatric area. (E) NGIS-type embryonal carcinoma. (F) NGIS and intratubular calcifications.
Anatomopathological results of the metastasis, diagnostic procedure and correlation with tumour markers.
| Anatomopathological diagnosis | Diagnostic procedures | Altered tumour markers | |
|---|---|---|---|
| GCT (Seminoma) | IOC-SBx of RTP tumour | LDH | |
| GCT (Seminoma) | FNAB-SBx of supraclavicular tumour | LDH | |
| GCT (Choriocarcinoma) | FNAB of lung tumour | HCG; LDH | |
| GCT (Seminoma) | RTP tumour biopsy | LDH | |
| Mixed GCT (EC/YST/T) | IOC-SBx of RTP tumour | HCG; AFP; LDH |
IOC: Intraoperative cytology; SBx: Surgical biopsy; RTP: retroperitoneum; FNAB: Fine needle aspiration biopsy; EC: embryonal carcinoma; YST: yolk sac tumour; T: teratoma.
General data from the 2000–2018 literature review.
| 1. Total Publications | 57 | |
| 2. Total Cases | 159 | |
| 3. Average age/range (years) | 35.96 | 17 - 67 |
| 4. Pathological history: | ||
| - Cryptorchidism | 9 | (15.8%) |
| - Contralateral GCT | 2 | (3.5%) |
| 5. GCT burned out: | ||
| - Metastatic | 154 | (96.8%) |
| - Non-metastatic | 5 | (3.2%) |
| 6. Testicular tumour regression: | ||
| - Complete | 114 | (71.7%) |
| - Partial | 45 | (28.3%) |
| 7. Affected testicle: | ||
| - Right | 74 | (47%) |
| - Left | 67 | (42%) |
| - Undetermined | 18 | (11%) |
| 8. Histological type of GCT: | In metastasis | In the testicle |
| - Pure seminoma | 81 (50.8%) | 23 (53.5%) |
| - Mixed with seminoma | 12 (7.4%) | 8 (18.7%) |
| - Mixed without seminoma | 17 (11.1%) | 3 (6.9%) |
| - Pure embryonal carcinoma | 16 (10.1%) | 2 (4.6%) |
| - Pure Choriocarcinoma | 4 (2.5%) | 0 |
| - Pure yolk sac tumour | 4 (2.5%) | 1 (2.3%) |
| -Teratoma | 5 (3.1%) | 6 (14%) |
| - Undetermined | 20 (12.5%) | NA |
| - Total | 159 (100%) | 43 (100%) |
Publications on spontaneous testicular GCT regression (2000–2018)
| No. | Author (Year)/bibliographic Ref. No. | No. cases | Age/Average (years) | GCT | 6. Testicular tumour regression: | ||
|---|---|---|---|---|---|---|---|
| Metastatic | No metastatic | Complete | Partial | ||||
| 1 | Leleu | 1 | 34 | 1 | 1 | ||
| 2 | Naseem | 2 | 34 | 1 | 1 | 1 | 1 |
| 3 | Scholz | 26 | 36 | 26 | 22 | 4 | |
| 4 | Kebapci | 1 | 22 | 1 | 1 | ||
| 5 | Bissen | 1 | 33 | 1 | 1 | ||
| 6 | Tasu | 5 | 31 | 5 | 3 | 2 | |
| 7 | Fabre | 5 | 34.6 | 4 | 1 | 4 | 1 |
| 8 | Mola | 1 | 33 | 1 | 1 | ||
| 9 | Perimenis | 1 | 40 | 1 | 1 | ||
| 10 | Castillo | 1 | 25 | 1 | 1 | ||
| 11 | Curigliano | 1 | 42 | 1 | 1 | ||
| 12 | Balzer and Ulbright (2006) [ | 42 | 32 | 42 | 26 | 16 | |
| 13 | Yamamoto | 1 | 39 | 1 | 1 | ||
| 14 | Parada | 2 | 19.5 | 2 | 2 | ||
| 15 | Patel and Patel (2007) [ | 1 | 23 | 1 | 1 | ||
| 16 | Vasquez | 3 | 38 | 3 | 3 | ||
| 17 | Coulier | 1 | 53 | 1 | 1 | ||
| 18 | Angulo | 17 | 31 | 17 | 10 | 7 | |
| 19 | Kontos | 1 | 31 | 1 | 1 | ||
| 20 | Ha | 1 | 23 | 1 | 1 | ||
| 21 | Yucel | 1 | 28 | 1 | 1 | ||
| 22 | Yucel | 1 | 49 | 1 | 1 | ||
| 23 | Mesa | 1 | 55 | 1 | 1 | ||
| 24 | Orlich and Jimenez (2010) [ | 1 | 33 | 1 | 1 | ||
| 25 | Gaytán | 1 | 19 | 1 | 1 | ||
| 26 | Jaber S. (2010) [ | 1 | 32 | 1 | 1 | ||
| 27 | Womeldorph | 1 | 55 | 1 | 1 | ||
| 28 | Musser | 1 | 63 | 1 | 1 | ||
| 29 | Herrera | 4 | 33 | 4 | 3 | 1 | |
| 30 | Balalaa | 1 | 31 | 1 | 1 | ||
| 31 | Kar | 1 | 33 | 1 | 1 | ||
| 32 | Preda | 1 | 43 | 1 | 1 | ||
| 33 | Gonzales | 1 | 35 | 1 | 1 | ||
| 34 | Peroux | 1 | 18 | 1 | 1 | ||
| 35 | Gurioli | 2 | 42.5 | 2 | 2 | ||
| 36 | Sahoo | 1 | 33 | 1 | 1 | ||
| 37 | Ichiyanagi et al (2013) [ | 1 | 47 | 1 | 1 | ||
| 38 | Miacola | 1 | 36 | 1 | 1 | ||
| 39 | Chung | 1 | 33 | 1 | 1 | ||
| 40 | Onishi | 1 | 41 | 1 | 1 | ||
| 41 | Qureshi | 1 | 20 | 1 | 1 | ||
| 42 | Budak | 1 | 39 | 1 | 1 | ||
| 43 | McCarthy | 1 | 24 | 1 | 1 | ||
| 44 | Gomis | 1 | 42 | 1 | 1 | ||
| 45 | Nguyen | 1 | 64 | 1 | 1 | ||
| 46 | Hu | 1 | 37 | 1 | 1 | ||
| 47 | George | 1 | 24 | 1 | 1 | ||
| 48 | Ishikawa | 1 | 42 | 1 | 1 | ||
| 49 | El sanharawi | 5 | 37 | 5 | 5 | ||
| 50 | Iwatsuki | 1 | 29 | 1 | 1 | ||
| 51 | Nakazaki. | 1 | 54 | 1 | 1 | ||
| 52 | El-sharkawy and Al-Jibali (2017) [ | 1 | 22 | 1 | 1 | ||
| 53 | Juul and Rasmussen (2017) [ | 1 | 57 | 1 | 1 | ||
| 54 | Mosillo | 1 | 19 | 1 | 1 | ||
| 55 | Nishisho | 1 | 30 | 1 | 1 | ||
| 56 | Ulloa-Ortiz | 1 | 52 | 1 | 1 | ||
| 57 | Freifeld | 1 | 44 | 1 | 1 | ||
| 159 | 35.9 | 154 | 5 | 114 | 45 | ||